Association between serum soluble TNFα receptors and renal dysfunction in type 2 diabetic patients without proteinuria

Diabetes Research and Clinical Practice

Volumn 92, Issue 2, 2011, Pages 174-180

  Miyazawa, Itsuko ^a   Araki, Shin ichi ^a   Obata, Toshiyuki ^a   Yoshizaki, Takeshi ^a   Morino, Katsutaro ^a   Kadota, Aya ^a   Ugi, Satoshi ^a   Kawai, Hiromichi ^a   Uzu, Takashi ^a   Nishio, Yoshihiko ^a   Koya, Daisuke ^b   Haneda, Masakazu ^c   Kashiwagi, Atsunori ^a   Maegawa, Hiroshi ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

^c ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Diabetic nephropathy; EGFR; Sex; STNFR1; STNFR2

Indexed keywords

INSULIN; ORAL ANTIDIABETIC AGENT; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 1; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIET THERAPY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; JAPANESE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK ASSESSMENT;

AGED; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; PROTEINURIA; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SEX FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79955798769     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.01.008     Document Type: Article

References (32)

1. Association AD Standards of medical care in diabetes-2010. Diab Care 2010, 33(Suppl. 1):S11-S61.
2. Adler A., Stevens R., Manley S., Bilous R., Cull C., Holman R. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003, 63:225-232.
3. Perkins B., Ficociello L., Ostrander B., Silva K., Weinberg J., Warram J., et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol 2007, 18:1353-1361.
4. Araki S., Haneda M., Koya D., Kashiwagi A., Uzu T., Kikkawa R. Clinical impact of reducing microalbuminuria in patients with type 2 diabetes mellitus. Diab Res Clin Pract 2008, 82(Suppl. 1):S54-S58.
5. Tonelli M., Wiebe N., Culleton B., House A., Rabbat C., Fok M., et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006, 17:2034-2047.
6. Araki S., Haneda M., Koya D., Sugimoto T., Isshiki K., Chin-Kanasaki M., et al. Predictive impact of elevated serum level of IL-18 for early renal dysfunction in type 2 diabetes: an observational follow-up study. Diabetologia 2007, 50:867-873.
7. Navarro-González J., Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008, 19:433-442.
8. Flyvbjerg A. Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily. Nat Rev Endocrinol 2010, 6:94-101.
9. Zoppini G., Faccini G., Muggeo M., Zenari L., Falezza G., Targher G. Elevated plasma levels of soluble receptors of TNF-alpha and their association with smoking and microvascular complications in young adults with type 1 diabetes. J Clin Endocrinol Metab 2001, 86:3805-3808.
10. Halwachs G., Tiran A., Reisinger E., Zach R., Sabin K., Fölsch B., et al. Serum levels of the soluble receptor for tumor necrosis factor in patients with renal disease. Clin Investig 1994, 72:473-476.
11. Rauchhaus M., Doehner W., Francis D., Davos C., Kemp M., Liebenthal C., et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000, 102:3060-3067.
12. Deswal A., Petersen N., Feldman A., Young J., White B., Mann D. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001, 103:2055-2059.
13. Matsuo S., Imai E., Horio M., Yasuda Y., Tomita K., Nitta K., et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009, 53:982-992.
14. The Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetol Int 2010, 1:2-20.
15. Lin J., Hu F., Mantzoros C., Curhan G. Lipid and inflammatory biomarkers and kidney function decline in type 2 diabetes. Diabetologia 2010, 53:263-267.
16. Yokoyama H., Sone H., Oishi M., Kawai K., Fukumoto Y., Kobayashi M. Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15). Nephrol Dial Transplant 2009, 24:1212-1219.
17. Vendrell J., Broch M., Fernandez-Real J., Gutiérrez C., Simón I., Megia A., et al. Tumour necrosis factor receptors (TNFRs) in type 2 diabetes. Analysis of soluble plasma fractions and genetic variations of TNFR2 gene in a case-control study. Diabet Med 2005, 22:387-392.
18. Kawasaki Y., Taniguchi A., Fukushima M., Nakai Y., Kuroe A., Ohya M., et al. Soluble TNF receptors and albuminuria in non-obese Japanese type 2 diabetic patients. Horm Metab Res 2005, 37:617-621.
19. Lin J., Hu F., Rimm E., Rifai N., Curhan G. The association of serum lipids and inflammatory biomarkers with renal function in men with type II diabetes mellitus. Kidney Int 2006, 69:336-342.
20. Niewczas M., Ficociello L., Johnson A., Walker W., Rosolowsky E., Roshan B., et al. Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 2009, 4:62-70.
21. Ng D., Fukushima M., Tai B., Koh D., Leong H., Imura H., et al. Reduced GFR and albuminuria in Chinese type 2 diabetes mellitus patients are both independently associated with activation of the TNF-alpha system. Diabetologia 2008, 51:2318-2324.
22. Keller C., Odden M., Fried L., Newman A., Angleman S., Green C., et al. Kidney function and markers of inflammation in elderly persons without chronic kidney disease: the health, aging, and body composition study. Kidney Int 2007, 71:239-244.
23. Keller C., Katz R., Cushman M., Fried L., Shlipak M. Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). BMC Nephrol 2008, 9:9.
24. Knight E., Rimm E., Pai J., Rexrode K., Cannuscio C., Manson J., et al. Kidney dysfunction, inflammation, and coronary events: a prospective study. J Am Soc Nephrol 2004, 15:1897-1903.
25. Tonelli M., Sacks F., Pfeffer M., Jhangri G., Curhan G. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 2005, 68:237-245.
26. Ernandez T., Mayadas T. Immunoregulatory role of TNFalpha in inflammatory kidney diseases. Kidney Int 2009, 76:262-276.
27. Pai J., Pischon T., Ma J., Manson J., Hankinson S., Joshipura K., et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004, 351:2599-2610.
28. Shai I., Schulze M., Manson J., Rexrode K., Stampfer M., Mantzoros C., et al. A prospective study of soluble tumor necrosis factor-alpha receptor II (sTNF-RII) and risk of coronary heart disease among women with type 2 diabetes. Diab Care 2005, 28:1376-1382.
29. Uzu T., Kida Y., Shirahashi N., Harada T., Yamauchi A., Nomura M., et al. Cerebral microvascular disease predicts renal failure in type 2 diabetes. J Am Soc Nephrol 2010, 21:520-526.
30. Thorand B., Baumert J., Döring A., Herder C., Kolb H., Rathmann W., et al. Sex differences in the relation of body composition to markers of inflammation. Atherosclerosis 2006, 184:216-224.
31. Ahonen T., Kautiainen H., Keinänen-Kiukaanniemi S., Kumpusalo E., Vanhala M. Gender difference among smoking, adiponectin, and high-sensitivity C-reactive protein. Am J Prev Med 2008, 35:598-601.
32. Saltevo J., Kautiainen H., Vanhala M. Gender differences in adiponectin and low-grade inflammation among individuals with normal glucose tolerance, prediabetes, and type 2 diabetes. Gend Med 2009, 6:463-470.